Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Dalenc

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancerP Cottu, V D'Hondt, S Dureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyS Delaloge, D Pérol, C Courtinard, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.
ESMO Open|November 26, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohortF Cherifi, L Cabel, C Bousrih, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2019
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysisA R Ferreira, A Di Meglio, B Pistilli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2021
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerA Bardia, S M Tolaney, K Punie, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancerP Cottu, V D'Hondt, S Dureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyS Delaloge, D Pérol, C Courtinard, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.
ESMO Open|November 26, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohortF Cherifi, L Cabel, C Bousrih, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2019
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysisA R Ferreira, A Di Meglio, B Pistilli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2021
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerA Bardia, S M Tolaney, K Punie, et al.
Pageof 5